Oct 22 (Reuters) - Thermo Fisher Scientific ( TMO )

raised its annual profit and revenue forecasts on Wednesday, as

the medical equipment maker expects robust demand for lab tools

and benefits from its recent acquisitions to offset a decline in

China.

Contract research firms such as Thermo Fisher are seeing

renewed demand for their services as pharmaceutical companies

ramp up drug development and manufacturing in the U.S. while

navigating President Donald Trump's shifting trade policies.

"There's a quiet confidence that they're going to be able to

navigate the government policies effectively, and you're seeing

that in some of the announcements that have been made on

pricing, as well as on reshoring," CEO Marc Casper said about

its pharmaceutical customers.

The Trump administration has extended some tariff exclusions

on China through November 29, but signaled potential new duties,

prompting Beijing to threaten countermeasures.

Thermo said its revenue from China will be down by

mid-to-high single-digit percentage due to the government's

program for buying medical devices in bulk at a sharp discount.

Its government and academic segment posted a slight

single-digit revenue decline, the management said, at a time

when the Trump administration has slashed academic research

funding by nearly 40%.

The company also expects a delay in some expenditures by the

U.S. government due to the shutdown, Casper said.

Thermo said it has benefited from recent deals such as the

purchase of Sanofi's New Jersey facility to produce critical

medicines and Solventum's purification and filtration business

for about $4.1 billion to expand in bioprocessing.

The company reported quarterly revenue of $11.12 billion,

compared with analysts' estimate of $10.91 billion, according to

data compiled by LSEG.

The Waltham, Massachusetts-based firm raised its annual

revenue forecast to a range of $44.1 billion to $44.5 billion

from $43.6 billion to $44.2 billion earlier.

It expects annual adjusted profit to be between $22.60

and $22.86 per share, compared with its previous range of $22.22

to $22.84 per share.

Thermo Fisher's quarterly profit per share of $5.79 beat

analysts' estimate of $5.49.